Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies

Oncotarget

Volumn 7, Issue 29, 2016, Pages 45283-45301

  Qi, Xingshun ^a   Li, Jianjun ^b   Deng, Han ^a   Li, Hongyu ^a   Su, Chunping ^c   Guo, Xiaozhong ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Inflammatory; Lymphocyte; Neutrophil; Prognosis

Indexed keywords

SORAFENIB;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NEUTROPHIL LYMPHOCYTE RATIO; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PROGNOSTIC ASSESSMENT; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW; IMMUNOLOGY; LIVER TUMOR; LYMPHOCYTE; MORTALITY; NEUTROPHIL; PROGNOSIS; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; LYMPHOCYTES; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; PROGNOSIS;

EID: 84979895782     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9942     Document Type: Article

References (108)

1. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009; 29:502-510.
2. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010; 30:61-74.
3. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28:751-755.
4. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014; 146:1691-1700 e1693.
5. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003; 38:207-215.
6. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964; 1:1-85.
7. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015; 33:550-558.
8. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883-899.
9. Wu Y, Zhao Q, Peng C, Sun L, Li XF, Kuang DM. Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop. J Pathol. 2011; 225:438-447.
10. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest. 2010; 120:1151-1164.
11. Nind AP, Nairn RC, Rolland JM, Guli EP, Hughes ES. Lymphocyte anergy in patients with carcinoma. Br J Cancer. 1973; 28:108-117.
12. Abdelmessih RM, Verna EC, Brubaker WD, Halazun KJ, Siegel A, Brown RS. Hepatocellular carcinoma tumor staging at the time of liver transplant but not at diagnosis are predictive of tumor recurrence in patients who are downstaged with chemoembolization. Hepatology. 2011; 54:1380A-1381A.
13. Afshar M, Clarke H, Jackson-Wilding A, Ahmed A, Ma YT, Punia P. Neutrophil lymphocyte ratio (NLR) at diagnosis is a predictor for survival in patients receiving sorafenib for advanced hepatocellular carcinoma (HCC): A large UK cohort. J Hepatol. 2015; 62:S442.
14. Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: Analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015; 220:416-427.
15. Aino H, Sumie S, Niizeki T, Kuromatsu R, Tajiri N, Nakano M, Satani M, Yamada S, Okamura S, Shimose S, Sumie H, Torimura T, Sata M. Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis. Mol Clin Oncol. 2014; 2:393-398.
16. Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, Cucchetti A, D'Errico-Grigioni A, Golfieri R, Pinna AD. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation. 2011; 91:1279-1285.
17. Bodzin A, Reino D, Lunsford K, Harlander-Locke M, Markovic D, Zarrinpar A, Kaldas F, Farmer D, Yersiz H, Busuttil R, Agopian V. Predictors of time to recurrence and mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation. Am J Transplant. 2015; 15:89.
18. Bronson N, Enestvedt K, Thomas E, Vermette D, Orloff S. Preoperative neutrophil to lymphocyte ratio does not predict recurrence or prognosis after resection for hepatocellular carcinoma. HPB. 2012; 14:456.
19. Bruixola G, Niño OM, Diaz-Beveridge R, Reche E, Salvador C, Escoin C, Akhoundova D, Segura A, Gimenez A, Aparicio J. Baseline neutrophil-to-lymphocyte ratio (NLR) and early toxicity as prognostic factors in advanced hepatocellular carcinoma patients treated with sorafenib. J Clin Oncol. 2015; 33.
20. Chan AW, Chan SL, Wong GL, Wong VW, Chong CC, Lai PB, Chan HL, To KF. Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. Ann Surg Oncol. 2015; 22:4138-4148.
21. Chang JX, Zeng Z, Lu YY, Qu HJ, Xu LG, Gao X, Wang H, Lou M, Wang C, Yang Y. Nlr of pro-cryoablation can predict the prognosis of patients with advanced hepatocellular carcinoma. Ann Oncol. 2014; 25:v45.
22. Chen TM, Lin CC, Huang PT, Wen CF. Neutrophilto-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol. 2012; 27:553-561.
23. Chen X, Zhai J, Cai X, Zhang Y, Wei L, Shi L, Wu D, Shen F, Lau WY, Wu M. Severity of portal hypertension and prediction of postoperative liver failure after liver resection in patients with Child-Pugh grade A cirrhosis. Br J Surg. 2012; 99:1701-1710.
24. Chen Z, Xy LI, Min DONG, Qu L, Xiaokun M, Xiangyuan WU. Identification of prognostic value of neutrophil-to-lymphocyte ratio (NLR) in patients with advanced hepatocellular carcinoma (HCC). Support Care Cancer. 2014; 22:S43.
25. da Fonseca LG, Barroso-Sousa R, Bento Ada S, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol. 2014; 31:264.
26. Dan J, Zhang Y, Peng Z, Huang J, Gao H, Xu L, Chen M. Postoperative Neutrophil-to-Lymphocyte Ratio Change Predicts Survival of Patients with Small Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. PLoS ONE. 2013; 8.
27. Facciorusso A, Del Prete V, Antonino M, Neve V, Crucinio N, Di Leo A, Carr BI, Barone M. Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. J Gastroenterol Hepatol. 2014; 29:1905-1910.
28. Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-tolymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS ONE. 2015; 10.
29. Fu SJ, Shen SL, Li SQ, Hua YP, Hu WJ, Liang LJ, Peng BG. Prognostic value of preoperative peripheral neutrophilto-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy. Med Oncol. 2013; 30.
30. Fu YP, Ni XC, Yi Y, Cai XY, He HW, Wang JX, Lu ZF, Zhou J, Fan J, Qiu SJ. A novel and validated inflammation based score (IBS) derived from neutrophil to lymphocyte ratio predicts survival in patients with hepatocellular carcinoma following curative surgical resection. Liver Cancer. 2015; 4:224.
31. Gao F, Li X, Geng M, Ye X, Liu H, Liu Y, Wan G, Wang X. Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. Medicine. 2015; 94:e639.
32. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR. Preoperative neutrophil-tolymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008; 32:1757-1762.
33. Guo ZX, Wei W, Zhong C, Shi M, Chen MS, Guo RP. Correlation of preoperative neutrophil-to-lymphocyte ratio to prognosis of young patients with hepatocellular carcinoma. Chin J Cancer. 2009; 28:75-80.
34. Halazun KJ, Hardy MA, Rana AA, Woodland DCt, Luyten EJ, Mahadev S, Witkowski P, Siegel AB, Brown RS Jr., Emond JC. Negative impact of neutrophillymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009; 250:141-151.
35. Harimoto N, Shirabe K, Nakagawara H, Toshima T, Yamashita Y, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/ lymphocyte ratio. Transplantation. 2013; 96:1008-1012.
36. Higashi T, Hayashi H, Kaida T, Arima K, Takeyama H, Taki K, Izumi D, Tokunaga R, Kosumi K, Nakagawa S, Okabe H, Imai K, Nitta H, et al. Prognostic Impact of Visceral Fat Amount and Branched-Chain Amino Acids (BCAA) in Hepatocellular Carcinoma. Ann Surg Oncol. 2015; 22:1041-1047.
37. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, Zhang X, Wang WM, Qiu SJ, Zhou J, Fan J. Systemic immuneinflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014; 20:6212-6222.
38. Huang GQ, Zhu GQ, Liu YL, Wang LR, Braddock M, Zheng MH, Zhou MT. Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection. Oncotarget. 2015.
39. Huang J, Xu L, Luo Y, He F, Zhang Y, Chen M. The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. Med Oncol. 2014; 31.
40. Huang ZL, Luo J, Chen MS, Li JQ, Shi M. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol. 2011; 22:702-709.
41. Kanno Y, Ishizuka M, Kubota K. Neutrophil to lymphocyte ratio is associated with postoperative survival of primary hepatocellular carcinoma patients undergoing curative surgery. Clin Nutr. 2014; 33:S242.
42. Kim DG. Neutrophil-lymphocyte ratio and serum C-reactive protein predict overall and recurrence free survival after liver transplantation in patients with hepatocellular carcinoma. Hepatology. 2013; 58:782A-783A.
43. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M. The C-Reactive Protein/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma. Ann Surg Oncol. 2015; 22:803-810.
44. Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int. 2014; 27:32-41.
45. Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Postoperative neutrophil-to-lymphocyte ratio plus plateletto-lymphocyte ratio predicts the outcomes of hepatocellular carcinoma. J Surg Res. 2015; 198:73-79.
46. Li JP, Hu SL, Chen H, Bu WZ, Song JL. Blood neutrophilto-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. Chinese Journal of Cancer Prevention and Treatment. 2013; 20:522-525.
47. Li X, Chen ZH, Ma XK, Chen J, Wu DH, Lin Q, Dong M, Wei L, Wang TT, Ruan DY, Lin ZX, Xing YF, Deng Y, et al. Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol. 2014; 35:11057-11063.
48. Li X, Han Z, Cheng Z, Yu J, Liu S, Yu X, Liang P. Preoperative neutrophil-to-lymphocyte ratio is a predictor of recurrence following thermal ablation for recurrent hepatocellular carcinoma: A retrospective analysis. PLoS ONE. 2014; 9.
49. Liao R, Tang ZW, Li DW, Luo SQ, Huang P, Du CY. Preoperative neutrophil-to-lymphocyte ratio predicts recurrence of patients with single-nodule small hepatocellular carcinoma following curative resection: A retrospective report. World J Surg Oncol. 2015; 13.
50. Liao W, Zhang J, Zhu Q, Qin L, Yao W, Lei B, Shi W, Yuan S, Tahir SA, Jin J, He S. Preoperative neutrophilto-lymphocyte ratio as a new prognostic marker in hepatocellular carcinoma after curative resection. Transl Oncol. 2014; 7:248-255.
51. Liese J, Peveling-Oberhag J, Moench C, Schnitzbauer A, Welker M, Zeuzem S, Bechstein W, Ulrich F. A possible role of miRNAs as predicitve markers for the recurrence of hepatocellular carcinoma after liver transplantation. Transplantation. 2014; 98:696.
52. Limaye AR, Clark V, Soldevila-Pico C, Morelli G, Suman A, Firpi R, Nelson DR, Cabrera R. Neutrophillymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Hepatol Res. 2013; 43:757-764.
53. Long J, Zheng JS, Sun B, Lu N. Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study. Hepatol Int. 2016; 1-10.
54. Lu D, Xu X, Zheng S. The prognostic capacity of microvascular invasion in liver transplantation for small hepatocellular carcinoma. Transplantation. 2015; 99:161-162.
55. Luè A, Bustamante FJ, Iñarrairaegui M, Arenas JI, Serrano MT, Testillano M, Lorente S, Gil C, De La Torre M, Gómez A, Sangro B. Neutrophil-to-lymphocyte ratio is a predictor of one-year survival in patients with hepatocellular carcinoma receiving sorafenib. J Hepatol. 2014; 60:S401.
56. Mano Y, Shirabe K, Yamashita Y, Harimoto N, Tsujita E, Takeishi K, Aishima S, Ikegami T, Yoshizumi T, Yamanaka T, Maehara Y. Preoperative neutrophil-tolymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg. 2013; 258:301-305.
57. McNally ME, Martinez A, Khabiri H, Guy G, Michaels AJ, Hanje J, Kirkpatrick R, Bloomston M, Schmidt CR. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Surg Oncol. 2013; 20:923-928.
58. Mizukoshi E, Yamashita T, Arai K, Terashima T, Kitahara M, Nakagawa H, Iida N, Fushimi K, Kaneko S. Myeloidderived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Hepatology. 2015; 62:408A.
59. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013; 58:58-64.
60. Na GH, Kim DG, Han JH, Kim EY, Lee SH, Hong TH, You YK. Inflammatory markers as selection criteria of hepatocellular carcinoma in living-donor liver transplantation. World J Gastroenterol. 2014; 20:6594-6601.
61. Nagai S, Mangus RS, Frost E, Kubal CA, Ekser B, Fridell JA, Kwo P, Maluccio MA, Tector AJ. Predictors for outcome of recurrence of hepatocellular carcinoma after liver transplantation: Successful treatment and long survival. Transplantation. 2015; 99:225.
62. Ni XC, Yi Y, Fu YP, He HW, Cai XY, Wang JX, Zhou J, Cheng YF, Jin JJ, Fan J, Qiu SJ. Prognostic value of the modified glasgow prognostic score in patients undergoing radical surgery for hepatocellular carcinoma. Medicine. 2015; 94.
63. Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, Lee S. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013; 13.
64. Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma. World J Surg. 2015; 39:1501-1509.
65. Parisi I, Tsochatzis E, Wijewantha H, Rodriguez-Peralvarez M, De Luca L, Manousou P, Fatourou E, Pieri G, Papastergiou V, Davies N, Yu D, Luong T, Dhillon AP, et al. Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. Liver Transpl. 2014; 20:1327-1335.
66. Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival. J Surg Res. 2014; 192:402-408.
67. Pinato DJ, Sharma R. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. Transl Res. 2012; 160:146-152.
68. Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, Kubota K, Sharma R. A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI). J Hepatol. 2012; 57:1013-1020.
69. Ruan DY, Lin ZX, Li Y, Jiang N, Li X, Wu DH, Wang TT, Chen J, Lin Q, Wu XY. Poor oncologic outcomes of hepatocellular carcinoma patients with intra-abdominal infection after hepatectomy. World J Gastroenterol. 2015; 21:5598-5606.
70. Shindoh J, Sugawara Y, Nagata R, Kaneko J, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, Tanaka T, Kokudo N. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma. Transpl Int. 2014; 27:391-398.
71. Sirin G, Senturk O, Yilmaz H, Celebi A, Hulagu S. Are inflammatory markers more useful than noninvasive fibrosis panels for prediction of hepatocellular carcinoma recurrence. Hepatol Int. 2015; 9:S290.
72. Sukato DC, Tohme S, Chalhoub D, Han K, Zajko A, Amesur N, Orons P, Marsh JW, Geller DA, Tsung A. The prognostic role of neutrophil-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma treated with radioembolization. J Vasc Interv Radiol. 2015; 26:816-824. e811.
73. Sullivan KM, Groeschl RT, Turaga KK, Tsai S, Christians KK, White SB, Rilling WS, Pilgrim CH, Gamblin TC. Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: a Western perspective. J Surg Oncol. 2014; 109:95-97.
74. Sun Q, Jiao SC, Wu JY, Long YY, Chen L. Pretreatment haematological laboratory values: The new prognostic factors in patients undergoing hepatectomy for hepatocellular carcinoma. Biomedical Research (India). 2014; 25:580-587.
75. Tajiri K, Baba H, Kawai K, Minemura M, Yasumura S, Takahara T, Sugiyama T. Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. J Gastroenterol Hepatol. 2016.
76. Tajiri K, Kawai K, Minemura M, Yasumura S, Hosokawa A, Kawabe H, Tomizawa G, Sugiyama T. Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil. Hepatol Res. 2015; 45:755-763.
77. Terashima T, Yamashita T, Iida N, Nakagawa H, Arai K, Kitamura K, Kagaya T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatol Res. 2015; 45:949-959.
78. Uchida K, Levi D, Nishida S, Selvaggi G, Tekin A, Taizo H, Garcia M, Feun L, Tzakis AG. Recurrence pattern and prognosis after liver transplant for hepatocellular carcinoma in the MELD ERA. Am J Transplant. 2012; 12:199-200.
79. Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, Zhu HB, Zhang Q, Chen GH. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS ONE. 2011; 6.
80. Wang K, Ling Q, Xu X, Wei Q, Chen J, Wu L, Zheng S. Does neutrophil to lymphocyte ratio improve hangzhou criteria for predicting tumor recurrence after liver transplantation? Liver Transplant. 2013; 19:S280-S281.
81. Wang Q, Blank S, Fiel MI, Kadri H, Luan W, Warren L, Zhu A, Deaderick PA, Sarpel U, Labow DM, Hiotis SP. The Severity of Liver Fibrosis Influences the Prognostic Value of Inflammation-Based Scores in Hepatitis B-Associated Hepatocellular Carcinoma. Ann Surg Oncol. 2015; 22:1125-1132.
82. Wang W, Ye Y, Wang T, Zhang F, Geng L, Yu J, Zhou L, Yan S, Zheng S. Prognostic prediction of male recipients selected for liver transplantation: With special attention to neutrophil-lymphocyte ratio. Hepatol Res. 2015.
83. Wei K, Wang M, Zhang W, Mu H, Song TQ. Neutrophillymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. Med Oncol. 2014; 31.
84. Weinmann AJ, Koch S, Sprinzl MF, Galle PR, Wörns M. Prognostic significance of inflammation based scores for patients with hepatocellular carcinoma treated with sorafenib in a western collective. Hepatology. 2015; 62:400A-401A.
85. Xiao GQ, Yang JY, Yan LN. Combined Hangzhou criteria with neutrophil-lymphocyte ratio is superior to other criteria in selecting liver transplantation candidates with HBVrelated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015; 14:588-595.
86. Xu X, Chen W, Zhang L, Miao R, Zhou Y, Wan Y, Dong Y, Liu C. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Chin Med J (Engl). 2014; 127:4204-4209.
87. Xue TC, Jia QA, Ge NL, Chen Y, Zhang BH, Ye SL. Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma. Tumour Biol. 2015; 36:8797-8803.
88. Yamamura K, Sugimoto H, Kanda M, Yamada S, Nomoto S, Nakayama G, Fujii T, Koike M, Fujiwara M, Kodera Y. Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. J Hepatobiliary Pancreat Sci. 2014; 21:682-688.
89. Yang X, Zhou S, Wen H, Li W, Li Z, Wu G, Sun Y, Wu H, Xu G. Preoperative neutrophil-lymphocyte ratio as a prognostic predictor after transarterial chemoembolization for HBV-associated hepatocellular carcinoma. Chin J Radiol. 2015; 49:769-773.
90. Yang Z, Zhang J, Lu Y, Xu Q, Tang B, Wang Q, Zhang W, Chen S, Lu L, Chen X. Aspartate aminotransferaselymphocyte ratio index and systemic immuneinflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolizations. Oncotarget. 2015; 6:43090-43098.
91. Yip V, Fenwick S, Malik H, Ghaneh P, Sarno G, Wu A, Terlizzo M, Poston G. Resection of hepatocellular carcinoma arising in noncirrhotic/non-fibrotic liver. HPB. 2011; 13:100-101.
92. Yoshizumi T, Harimoto N, Itoh S, Okabe H, Kimura K, Uchiyama H, Ikegami T, Ikeda T, Maehara Y. Living Donor Liver Transplantation for Hepatocellular Carcinoma within Milan Criteria in the Present Era. Anticancer Res. 2016; 36:439-445.
93. Yoshizumi T, Ikegami T, Toshima T, Harimoto N, Uchiyama H, Soejima Y, Yamashita Y, Shirabe K, Maehara Y. Two-step selection criteria for living donor liver transplantation in patients with hepatocellular carcinoma. Transplant Proc. 2013; 45:3310-3313.
94. Yoshizumi T, Ikegami T, Yoshiya S, Motomura T, Mano Y, Muto J, Ikeda T, Soejima Y, Shirabe K, Maehara Y. Impact of tumor size, number of tumors and neutrophilto-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. Hepatol Res. 2013; 43:709-716.
95. Young AL, Adair R, Prasad KR, Toogood GJ, Lodge JP. Hepatocellular carcinoma within a noncirrhotic, nonfibrotic, seronegative liver: surgical approaches and outcomes. J Am Coll Surg. 2012; 214:174-183.
96. Zhang J, Gong F, Li L, Zhao M, Song J. Diabetes mellitus and the neutrophil to lymphocyte ratio predict overall survival in non-viral hepatocellular carcinoma treated with transarterial chemoembolization. Oncol Lett. 2014; 7:1704-1710.
97. Zhang W, Zhao G, Wei K, Zhang Q, Ma W, Wu Q, Zhang T, Kong D, Li Q, Song T. Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors. Med Oncol. 2015; 32.
98. Zheng YB, Zhao W, Liu B, Li Y, Hu BS, Lu LG. Prognostic significance of blood neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma undergoing TACE. Chinese Journal of Interventional Imaging and Therapy. 2013; 10:523-526.
99. Zheng YB, Zhao W, Liu B, Lu LG, He X, Huang JW, Li Y, Hu BS. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev. 2013; 14:5527-5531.
100. Zhou D, Zhang Y, Xu L, Zhou Z, Huang J, Chen M. A monocyte/granulocyte to lymphocyte ratio predicts survival in patients with hepatocellular carcinoma. Sci Rep. 2015; 5:15263.
101. Zhou DS, Xu L, Luo YL, He FY, Huang JT, Zhang YJ, Chen MS. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. World J Gastroenterol. 2015; 21:5582-5590.
102. Xiao WK, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: A meta-analysis. BMC Cancer. 2014; 14.
103. Xue TC, Zhang L, Xie XY, Ge NL, Li LX, Zhang BH, Ye SL, Ren ZG. Prognostic significance of the neutrophilto-lymphocyte ratio in primary liver cancer: A metaanalysis. PLoS ONE. 2014; 9.
104. Lu SD, Wang YY, Peng NF, Peng YC, Zhong JH, Qin HG, Xiang BD, You XM, Ma L, Li LQ. Preoperative Ratio of Neutrophils to Lymphocytes Predicts Postresection Survival in Selected Patients With Early or Intermediate Stage Hepatocellular Carcinoma. Medicine. 2016; 95:e2722.
105. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://wwwohrica/programs/clinical_epidemiology/oxfordasp.
106. Qi X, Liu L, Wang D, Li H, Su C, Guo X. Hepatic resection alone versus in combination with pre-and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and metaanalysis. Oncotarget. 2015; 6:36838-36859.
107. Qi X, Wang D, Su C, Li H, Guo X. Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and metaanalysis. Oncotarget. 2015; 6:18715-18733.
108. Qi X, Tang Y, An D, Bai M, Shi X, Wang J, Han G, Fan D. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2014; 48:450-457.